We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Next-Gen IVD LC-MS/MS System 5X More Sensitive for Quantifying Analytes in Saliva, Breath and Dried Blood Spots

By LabMedica International staff writers
Posted on 06 Apr 2023
Print article
Image: The new MassTrak IVD LC-MS/MS System featuring the Xevo TQ Absolute IVD tandem quadrupole mass spectrometer (Photo courtesy of Waters)
Image: The new MassTrak IVD LC-MS/MS System featuring the Xevo TQ Absolute IVD tandem quadrupole mass spectrometer (Photo courtesy of Waters)

As energy expenses increase dramatically and laboratory spaces remain in high demand, the need for an analytical instrument that can perform complex trace analyte quantification and increase in-house testing while also reducing energy consumption and saving lab space has become critical. Now, an extremely compact and sustainable analytical instrument accurately quantifies trace analytes with outstanding precision. This powerful instrument can improve patient care, generate cost savings, and meet a laboratory's unique analytical workflow requirements with its vast array of customizable options.

Waters Corporation (Milford, MA, USA) has introduced its next-generation Xevo TQ Absolute IVD mass spectrometer, expanding its family of MassTrak IVD LC-MS/MS Systems for clinical diagnostic applications. The new MassTrak LC-MS/MS IVD system now comprises the ACQUITY UPLC I-Class PLUS liquid chromatography instrument and the Xevo TQ Absolute IVD mass spectrometer. The ACQUITY UPLC I-Class PLUS System is designed to provide fast and precise sample analysis to improve mass spectrometer sensitivity and simplify complex sample characterization. The Xevo TQ Absolute IVD System is more consistent than other tandem quadrupole-mass spectrometry (TQ-MS) systems, with a user-friendly design that maximizes service uptime. Additionally, it is 45% smaller and uses 50% less nitrogen gas and electricity than comparable TQ-MS systems, making it ideal for hospital and commercial labs seeking to reduce energy consumption and save space.

The Xevo TQ Absolute IVD mass spectrometer offers exceptional analytical performance, with up to five times greater sensitivity for quantifying clinical analytes compared to other commercial instruments available. This heightened sensitivity allows clinical laboratories to detect and measure trace-level analytes within a sample, reaching detection levels previously unattainable. This capability expands the testing capabilities of clinical laboratories, making it possible to work with lower volume samples obtained from less invasive assays such as saliva, breath, and dried blood spots. Additionally, the system empowers clinical laboratories to expand their test menu to include multiplex panels and large molecules.

“Waters’ MassTrak IVD systems gives clinical diagnostic laboratories highly precise and flexible options that ultimately enable clinicians to provide better patient care,” said Jianqing Bennett, Waters Corporation Senior Vice President of the Waters Clinical Business Unit. “Adding the Xevo TQ Absolute IVD to the MassTrak IVD family offers customers class-leading sensitivity and analytical performance. Waters is uniquely positioned to enable clinical laboratories to develop reliable test methods for difficult analytes, helping them expand their capabilities to manage emerging remote sampling techniques.”

Related Links:
Waters Corporation 

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Calprotectin Assay
Fecal Calprotectin ELISA
New
HbA1c Test
HbA1c Rapid Test

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.